Choriogonadotropin alfa
Identification
- Summary
Choriogonadotropin alfa is a recombinant form of human chorionic gonadotropin used to treat female infertility by inducing ovulation.
- Brand Names
- Ovidrel, Ovitrelle, Pregnyl
- Generic Name
- Choriogonadotropin alfa
- DrugBank Accession Number
- DB00097
- Background
Recombinant human chorionic gonadotropin with 2 subunits, alpha = 92 residues, beta = 145 residues, each with N-and O-linked carbohydrate moieties linked to ASN-52 and ASN-78 (on alpha subunit) and ASN-13, ASN-30, SER-121, SER-127, SER-132 and SER-138 (on beta subunit). The primary structure of the alpha-chain of r-hCG is identical to that of the alpha-chain of hCG, FSH and LH.
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Protein Based Therapies
Hormones - Protein Structure
- Protein Chemical Formula
- C1105H1770N318O336S26
- Protein Average Weight
- 25719.7 Da
- Sequences
>Alpha chain APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCC VAKSYNRVTVMGGFKVENHTACHCSTCYYHKS
>Beta chain SKEPLRPRCRPINATLAVEKEGCPVCITVNTTICAGYCPTMTRVLQGVLPALPQVVCNYR DVRFESIRLPGCPRGVNPVVSYAVALSCQCALCRRSTTDCGGPKDHPLTCDDPRFQDSSS SKAPPPSLPSPSRLPGPSDTPILPQ
Download FASTA Format- Synonyms
- Choriogonadotropin alfa
- Choriogonadotropin alpha
- Chorionic gonadotropin (recombinant)
Pharmacology
- Indication
For the treatment of female infertility
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Management of Secondary hypogonadotrophic hypogonadism •••••••••••• •••••••••• ••• - Associated Therapies
- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Choriogonadotropin alfa is used to treat female infertility, Choriogonadotropin alfa stimulates late follicular maturation and resumption of oocyte meiosis, and initiates rupture of the pre-ovulatory ovarian follicle. Ovidrel is an analogue of Luteinizing Hormone (LH) and binds to the LH/hCG receptor of the granulosa and theca cells of the ovary to effect these changes in the absence of an endogenous LH surge.
- Mechanism of action
Choriogonadotropin alfa binds to the Follicle stimulating hormone receptor which results in ovulation in the absence of sufficient endogenous Luteinizing hormone.
Target Actions Organism ALutropin-choriogonadotropic hormone receptor Not Available Humans AFollicle-stimulating hormone receptor binderHumans - Absorption
The mean absolute bioavailability following a single subcutaneous injection to healthy female volunteers is about 40%.
- Volume of distribution
- 5.9 ± 1.0 L
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
One-tenth of the dose is excreted in the urine.
- Half-life
The mean terminal half-life is about 29 ± 6 hours (initial half-life is 4.5 ± 0.5 hours).
- Clearance
- 0.29 +/- 0.04 L/h [healthy down-regulated females]
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- International/Other Brands
- Profasi (Serono S.A.)
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Chorionic Gonadotropin Kit 10000 [USP'U]/10mL Intramuscular Physicians Total Care, Inc. 2007-07-13 2008-06-30 US Chorionic Gonadotropin Kit 10000 [USP'U]/10mL Intramuscular Fresenius Kabi USA, LLC 2011-04-21 Not applicable US Chorionic Gonadotropin Kit 10000 [USP'U]/10mL Intramuscular APP Pharmaceuticals, LLC 2011-04-21 2011-04-20 US Ovidrel Solution 250 mcg / 0.5 mL Subcutaneous Emd Serono, A Division Of Emd Inc., Canada 2013-05-28 Not applicable Canada Ovidrel Solution 250 mcg / 0.5 mL Subcutaneous Emd Serono, A Division Of Emd Inc., Canada 2004-12-20 Not applicable Canada
Categories
- ATC Codes
- G03GA08 — Choriogonadotropin alfa
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 6413W06WR3
- CAS number
- 177073-44-8
References
- General References
- Kayisli UA, Selam B, Guzeloglu-Kayisli O, Demir R, Arici A: Human chorionic gonadotropin contributes to maternal immunotolerance and endometrial apoptosis by regulating Fas-Fas ligand system. J Immunol. 2003 Sep 1;171(5):2305-13. [Article]
- Askling J, Erlandsson G, Kaijser M, Akre O, Ekbom A: Sickness in pregnancy and sex of child. Lancet. 1999 Dec 11;354(9195):2053. [Article]
- External Links
- UniProt
- P01233
- Genbank
- J00117
- PubChem Substance
- 46506863
- 283550
- ChEMBL
- CHEMBL1201464
- Therapeutic Targets Database
- DAP001030
- PharmGKB
- PA164783947
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Human_chorionic_gonadotropin
- FDA label
- Download (97.1 KB)
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Completed Prevention BRCA 1 Gene Mutation / BRCA 2 Gene Mutation / HCG 1 4 Completed Treatment Female Infertility / In Vitro Fertilization (IVF) / Ovarian Reserve 1 4 Completed Treatment Infertile Women Undergoing Assisted Reproductive Technology (ART) 1 4 Completed Treatment Infertility 2 4 Completed Treatment Infertility / Progesterone Levels 1
Pharmacoeconomics
- Manufacturers
- Emd serono inc
- Ferring pharmaceuticals inc
- App pharmaceuticals llc
- Bel mar laboratories inc
- Bristol myers squibb
- Organon usa inc
- Packagers
- EMD Canada Inc.
- Ferring Pharmaceuticals Inc.
- Merck KGaA
- Organon Pharmaceuticals
- Dosage Forms
Form Route Strength Injection, solution Subcutaneous 250 ug/0.5mL Solution Subcutaneous 250 mcg / 0.5 mL Solution Subcutaneous 250.00 mcg Injection, solution Subcutaneous Injection, solution Subcutaneous 250 mcg Injection, powder, for solution Subcutaneous 250 MCG Injection, solution Subcutaneous 250 micrograms Injection, solution Subcutaneous 250 micrograms/0.5ml Injection, solution Subcutaneous 250 MCG/0.5ML Injection, powder, lyophilized, for solution; kit Intramuscular 10000 [USP'U]/10mL Kit Intramuscular 10000 [USP'U]/10mL - Prices
Unit description Cost Unit Novarel 10000 unit/10ml Solution 1 Vial = 10ml 118.55USD vial Novarel 10000 unit vial 113.99USD vial Ovidrel 250 mcg/0.5ml Injectable 0.5ml Syringe 93.22USD syringe Pregnyl 10000 unit Solution 60.7USD vial Pregnyl 10000 unit vial 57.23USD vial DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US5767251 No 1998-06-16 2015-06-16 US US6706681 No 2004-03-16 2021-03-16 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 55 °C Forastieri, H., Ingham, K.C. J. Biol. Chem. 257:7976-7981 (1982) hydrophobicity -0.258 Not Available isoelectric point 8.61 Not Available
Targets
![](https://go.drugbank.com/assets/locked/DrugTargets2-682eb846d210ae4bf33ca03febccfb57bb1c61318e699b729e5df4dfab2c5b67.png)
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- General Function
- Luteinizing hormone receptor activity
- Specific Function
- Receptor for lutropin-choriogonadotropic hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase.
- Gene Name
- LHCGR
- Uniprot ID
- P22888
- Uniprot Name
- Lutropin-choriogonadotropic hormone receptor
- Molecular Weight
- 78642.01 Da
References
- Bodek G, Vierre S, Rivero-Muller A, Huhtaniemi I, Ziecik AJ, Rahman NA: A novel targeted therapy of Leydig and granulosa cell tumors through the luteinizing hormone receptor using a hecate-chorionic gonadotropin beta conjugate in transgenic mice. Neoplasia. 2005 May;7(5):497-508. [Article]
- Gromoll J, Wistuba J, Terwort N, Godmann M, Muller T, Simoni M: A new subclass of the luteinizing hormone/chorionic gonadotropin receptor lacking exon 10 messenger RNA in the New World monkey (Platyrrhini) lineage. Biol Reprod. 2003 Jul;69(1):75-80. Epub 2003 Feb 19. [Article]
- Lin W, Bernard MP, Cao D, Myers RV, Kerrigan JE, Moyle WR: Follitropin receptors contain cryptic ligand binding sites. Mol Cell Endocrinol. 2007 Jan 2;260-262:83-92. Epub 2006 Oct 23. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Binder
- General Function
- G-protein coupled peptide receptor activity
- Specific Function
- Receptor for follicle-stimulating hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Induces cAMP production through the activation of PI3K-AKT and S...
- Gene Name
- FSHR
- Uniprot ID
- P23945
- Uniprot Name
- Follicle-stimulating hormone receptor
- Molecular Weight
- 78264.07 Da
References
- Jameson JL: Inherited disorders of the gonadotropin hormones. Mol Cell Endocrinol. 1996 Dec 20;125(1-2):143-9. [Article]
- Lin W, Bernard MP, Cao D, Myers RV, Kerrigan JE, Moyle WR: Follitropin receptors contain cryptic ligand binding sites. Mol Cell Endocrinol. 2007 Jan 2;260-262:83-92. Epub 2006 Oct 23. [Article]
- Tao YX, Segaloff DL: Follicle stimulating hormone receptor mutations and reproductive disorders. Prog Mol Biol Transl Sci. 2009;89:115-31. doi: 10.1016/S1877-1173(09)89005-4. Epub 2009 Oct 7. [Article]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
Drug created at June 13, 2005 13:24 / Updated at February 20, 2024 23:55